Projects per year
Personal profile
Biography
Biographical Sketch Honorary Professor John Wilson
BSc(Hons), MBBS, PhD, FRACP, FCCP, MAICD.
John Wilson graduated in Science with BSc(Hons) from The University of Melbourne in 1975 with a major interest in physics and information technology. He then qualified in Medicine in 1980 (MBBS). His physician training was at The Royal Melbourne Hospital, with a special interest in intensive care and respiratory medicine. He studied the role of inflammation in asthma and completed his PhD before moving to the UK to join a major asthma research group in 1988. After returning to Australia in 1990, he spent 2 years at Royal Melbourne Hospital as Assistant Physician, then joined The Department of Respiratory Medicine at The Alfred Hospital Melbourne as Respiratory Physician and Head of the Cystic Fibrosis Service. In this role he has received DHS Centre of Excellence, NHMRC and ARC funding, as well as service achievement awards. He is responsible for the treatment of patients with different lung disorders, including cystic fibrosis, asthma and pneumonia. His research interests include the use of video-conferencing in delivering care programs, the application of electronic health records to medical systems and new pharmacological treatments in CF lung disease.
He heads Monashalliance (www.monashalliance.com) which aims to implement eHealth initiatives in clinical care.
He has been elected to the Board, The Royal Australasian College of Physicians (past President, Adult Medicine Division and Board member), a consultant to industry in Australia and overseas, a member of The Alfred Hospital Ethics Committee and has been Director of Physician Training there.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Lung disorders
- Respiratory medicine
- Cystic Fibrosis
- Asthma
- Pneumonia
Network
-
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for 508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation.
Kotsimbos, A. T. & Wilson, J.
1/03/22 → 31/12/24
Project: Research
-
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneoulsy Administered ELX-02 in Patients with Cystic Fibrosis with at Least One G542X Allele.
Wilson, J., Burr, L. D., Morton, J. M. & Visser, S. K.
1/02/21 → 31/12/24
Project: Research
-
Feasibility of the A-STEP for the assessment of exercise capacity in people with cystic fibrosis
Wilson, L. M., Potter, A., Maher, C., Ellis, M. J., Lane, R. L., Wilson, J. W., Keating, D. T., Jaberzadeh, S. & Button, B. M., Oct 2022, In: Pediatric Pulmonology. 57, 10, p. 2524-2532 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension
King, S. J., Tierney, A. C., Edgeworth, D., Keating, D., Williams, E., Kotsimbos, T., Button, B. M. & Wilson, J. W., May 2021, In: Nutrition. 85, 8 p., 111124.Research output: Contribution to journal › Article › Research › peer-review
13 Citations (Scopus) -
Development of the A-STEP: A new incremental maximal exercise capacity step test in cystic fibrosis
Wilson, L. M., Ellis, M. J., Lane, R. L., Wilson, J. W., Keating, D. T., Jaberzadeh, S. & Button, B. M., Dec 2021, In: Pediatric Pulmonology. 56, 12, p. 3777-3784 8 p.Research output: Contribution to journal › Article › Research › peer-review
3 Citations (Scopus) -
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
Hanafin, P. O., Sermet-Gaudelus, I., Griese, M., Kappler, M., Ellemunter, H., Schwarz, C., Wilson, J., Tan, M., Velkov, T., Rao, G. G. & Schneider-Futschik, E. K., 2 Aug 2021, In: Frontiers in Pharmacology. 12, 9 p., 577263.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
The AWESCORE, a patient-reported outcome measure: Development, feasibility, reliability, validity and responsiveness for adults with cystic fibrosis
Button, B. M., Wilson, L. M., Burge, A. T., Kimmel, L., Finlayson, F., Williams, E., Talbot, A., Tierney, A., King, S., Holland, A. E., Keating, D., Kotsimbos, T. & Wilson, J. W., 1 Jul 2021, In: ERJ Open Research. 7, 3, 8 p., 00120-2021.Research output: Contribution to journal › Article › Research › peer-review
Open Access